Professor Shi Yuanyuan was invited to visit the Interventional and Cell Therapy Center of Peking University Shenzhen Hospital
Recently, Professor Shi Yuanyuan, founder and chairman of Shenzhen Cell Valley Biomedicine Co., LTD., Yang Bolui, Executive President of Guangdong Junhou Biomedicine, a wholly-owned subsidiary, and Dr. Feng Yaru, vice president, were invited to visit the Interventional and Cell Therapy Center of Peking University Shenzhen Hospital. Professor Fan Dayue, director of the Center and consultant of the center, warmly received him.
Chen Junhui, director of the Interventional and Cell Therapy Center of Peking University Shenzhen Hospital, introduced the overall situation of Peking University Shenzhen Hospital to Chairman Shi Yuan and his delegation, and gave a detailed introduction to the interventional and cell therapy center.
At the symposium, Director Chen Junhui first introduced the history and current situation of the center (see introduction). Director Chen introduced in detail the development and operation of the "National Stem Cell Clinical Research Institute" clinical research project under his leadership, the Phase I clinical trial Center of the National Drug Clinical Trial Institute, and the Interventional and Cell Therapy Center in various aspects of medicine, education and research. Director Chen mentioned the clinical situation and experience summary of cancer patients receiving cell therapy in the center, said that it is necessary to focus on the safety of cell therapy, for adverse reactions such as cytokine storms, clinical teams should constantly weigh the risks and benefits of different treatments, and strengthen scientific research on early diagnosis of adverse reactions.
Subsequently, President Shi Yuan and Vice President Feng Yaru respectively introduced the development layout and strategic positioning of Shenzhen Cell Valley South China Cell Factory, a one-stop cell and gene therapy CRO/CDMO service platform, and the production process of retroviral vector and cell products. Chairman Shi Yuanyuan said that Shenzhen Cell Valley has mastered the only domestic clinical-grade industrial production process of inverse virus vector, which can effectively solve the problem of "technology stuck neck" in China's cell gene therapy industry.
Chen Junhui, director of the Interventional and Cell Therapy Center of Peking University Shenzhen Hospital, introduced the overall situation of Peking University Shenzhen Hospital to Chairman Shi Yuan and his delegation, and gave a detailed introduction to the interventional and cell therapy center.
At the symposium, Director Chen Junhui first introduced the history and current situation of the center (see introduction). Director Chen introduced in detail the development and operation of the "National Stem Cell Clinical Research Institute" clinical research project under his leadership, the Phase I clinical trial Center of the National Drug Clinical Trial Institute, and the Interventional and Cell Therapy Center in various aspects of medicine, education and research. Director Chen mentioned the clinical situation and experience summary of cancer patients receiving cell therapy in the center, said that it is necessary to focus on the safety of cell therapy, for adverse reactions such as cytokine storms, clinical teams should constantly weigh the risks and benefits of different treatments, and strengthen scientific research on early diagnosis of adverse reactions.
Subsequently, President Shi Yuan and Vice President Feng Yaru respectively introduced the development layout and strategic positioning of Shenzhen Cell Valley South China Cell Factory, a one-stop cell and gene therapy CRO/CDMO service platform, and the production process of retroviral vector and cell products. Chairman Shi Yuanyuan said that Shenzhen Cell Valley has mastered the only domestic clinical-grade industrial production process of inverse virus vector, which can effectively solve the problem of "technology stuck neck" in China's cell gene therapy industry.
